Clinical Research Directory
Browse clinical research sites, groups, and studies.
SNV4818 in Participants With Advanced Solid Tumors
Sponsor: Pikavation Therapeutics, Inc.
Summary
This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.
Official title: A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
320
Start Date
2025-02-20
Completion Date
2027-06
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Interventions
SNV4818
SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Fulvestrant
Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)
Palbociclib
Palbociclib tablets will be administered by mouth on days 1-21 of a 28 day cycle. The Palbociclib starting dose will be 125 mg once-daily
Locations (12)
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
Los Angeles, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Thomas Jefferson University-Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Scientia Clinical Research
Randwick, New South Wales, Australia
Monash Health
Clayton, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada